公开(公告)号：EP1709058A2

公开(公告)日：2006-10-11

申请号：EP04811574.5

申请日：2004-11-22

申请人： Genaissance Pharmaceuticals, Inc.

发明人： AERSSENS, Jeroen ,  ATHANASIOU, Maria ,  BRAIN, Carlos ,  COHEN, Nadine ,  DAIN, Bradley ,  DENTON, R., Rex ,  JUDSON, Richard, S. ,  OZDEMIR, Vural ,  REED, Carol, R.

IPC分类号： C07H21/04 ,  C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16 ,  C12Q2600/172

摘要： Haplotypes in the NTRK1 gene associated with progression of Alzheimer’s Disease are disclosed. Compositions and methods for detecting these NTRK1 haplotypes are disclosed.

公开(公告)号：EP1646729A2

公开(公告)日：2006-04-19

申请号：EP04778129.9

申请日：2004-07-12

申请人： Genaissance Pharmaceuticals, Inc.

发明人： AERSSENS, Jeroen ,  ATHANASIOU, Maria ,  BRAIN, Carlos ,  COHEN, Nadine ,  DAIN, Bradley ,  DENTON, R., Rex ,  JUDSON, Richard, S. ,  OZDEMIR, Vural ,  REED, Carol, R.

IPC分类号： C12Q1/68 ,  C07D491/10 ,  A61K31/554

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

摘要： Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 hyplotypes in a variety of clinical applications are disclosed. Such applications include articles of a manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer’s patients based upon their haplotype profile.

公开(公告)号：EP1678328A2

公开(公告)日：2006-07-12

申请号：EP04794919.3

申请日：2004-10-14

申请人： Genaissance Pharmaceuticals, Inc.

发明人： AERSSENS, Jeroen ,  ATHANASIOU, Maria ,  BRAIN, Carlos ,  COHEN, Nadine ,  DAIN, Bradley ,  DENTON, R., Rex ,  JUDSON, Richard, S. ,  OZDEMIR, Vural ,  REED, Carol, R.

IPC分类号： C12Q1/68 ,  A61K49/00 ,  C12P19/34 ,  A01N25/34 ,  C07H21/04 ,  A01N61/00

CPC分类号： G01N33/6896 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/16 ,  C12Q2600/172

摘要： Haplotypes in the NTRK1 gene associated with age of onset of Alzheimer’s Disease are disclosed. Compositions and methods for detecting and using these NTRK1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these NTRK1 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.

公开(公告)号：EP1208421A2

公开(公告)日：2002-05-29

申请号：EP00941722.1

申请日：2000-06-26

申请人： Genaissance Pharmaceuticals, Inc.

发明人： DENTON, Richard, Rex ,  JUDSON, Richard, S. ,  RUANO, Gualberto ,  STEPHENS, Joel, Claiborne ,  WINDEMUTH, Andreas, K. ,  XU, Chuanbo

IPC分类号： G06F7/00 ,  G06F17/00 ,  G01N33/48 ,  G01N33/50 ,  G06T1/00

CPC分类号： G06F19/18 ,  G06F19/14 ,  G06F19/22 ,  G06F19/24 ,  G06F19/26 ,  G06F19/28 ,  G16H10/20 ,  Y02A90/22 ,  Y02A90/26

摘要： Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's gen type for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.